In the evaluation of patients with KRAS mutations in terms of tumor stage, the median stage of the wild-type patients was 4 (3‒4), and the median stage of the mutant-type patients was 4 (4‒4) (p = 0.601). The gene discussed is KRAS; the disease is neoplasm.